Pharmacological inhibition of FGF receptor signaling inhibits LNCaP prostate tumor growth, promatrilysin, and PSA expression

Thirupandiyur S. Udayakumar(Fox Chase Cancer Center), G. Timothy Bowden(University of Arizona), Raymond B. Nagle(University of Arizona), Elisabeth L. Bair

Molecular Carcinogenesis

September 15, 2003

10.1002/mc.10146

Cited by 19

Related Papers

Liposomes: Clinical Applications and Potential for Image-Guided Drug Delivery

|Molecules|2018|303

Membrane type-1-matrix metalloproteinase expressed by prostate carcinoma cells cleaves human laminin-5 beta3 chain and induces cell migration.

|PubMed|2003|131

Comparison of two-stage epidermal carcinogenesis initiated by 7,12-dimethylbenz(a)anthracene or N-methyl-N'-nitro-N-nitrosoguanidine in newborn and adult SENCAR and BALB/c mice.

|PubMed|1981|100

Inhibition of Activator Protein-1 by Sulforaphane Involves Interaction with Cysteine in the cFos DNA-Binding Domain: Implications for Chemoprevention of UVB-Induced Skin Cancer

|Cancer Research|2009|78

Different Phenotypes in Human Prostate Cancer: α6 or α3 Integrin in Cell-extracellular Adhesion Sites

|Neoplasia|2002|74